로저스 (ROG)

전일 마감가:

$109.54

열려 있는:

$120.74

하루 거래량:

577.29K

시가총액:

$2.26B

수익:

$908.40M

순이익/손실:

$56.60M

주가수익비율:

22.54

EPS:

5.37

순현금흐름:

$74.40M

1주 성능:

+10.87%

1개월 성능:

+2.54%

6개월 성능:

+1.61%

1년 성능:

-21.68%

1일 변동 폭

$117.31

$126.40

52주 변동 폭

$105.48

$173.16

로저스 Stock (ROG) Company Profile

명칭

Rogers Corp.

부문

Technology (769)

산업

Electronic Components (46)

전화

480-917-6000

주소

2225 West Chandler Boulevard, Chandler, AZ

직원

3,400

트위터

@Rogers_Corp

다음 수익 날짜

2024-05-01

최신 SEC 제출 서류

ROG's Discussions on Twitter

로저스 Stock (ROG) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-14	개시	CJS Securities	Market Outperform
2023-02-14	재개	B. Riley Securities	Buy
2021-12-14	다운그레이드	CJS Securities	Market Outperform → Market Perform
2021-06-10	개시	Wolfe Research	Outperform
2021-05-26	개시	Canaccord Genuity	Buy
2019-05-31	개시	Stifel	Buy
2019-02-21	재확인	B. Riley FBR	Buy
2018-09-18	재확인	B. Riley FBR	Buy
2018-09-06	재개	Sidoti	Buy
2018-03-01	재확인	Needham	Buy
2017-11-03	재확인	B. Riley FBR, Inc.	Buy
2017-04-28	재확인	Needham	Buy
2017-04-11	업그레이드	Sidoti	Neutral → Buy
2016-11-16	다운그레이드	Sidoti	Buy → Neutral
2016-09-13	개시	Needham	Buy
2016-03-11	개시	Drexel Hamilton	Buy
2015-10-02	개시	B. Riley & Co.	Neutral
2014-11-17	재확인	DA Davidson	Buy
2014-07-18	재확인	DA Davidson	Buy
2014-04-30	업그레이드	DA Davidson	Neutral → Buy
2012-02-17	업그레이드	DA Davidson	Neutral → Buy
2012-01-06	재확인	JMP Securities	Mkt Outperform
2011-12-21	개시	JMP Securities	Mkt Outperform
2011-12-02	개시	Rodman & Renshaw	Mkt Outperform
2008-12-17	개시	DA Davidson	Neutral

모두보기

로저스 주식(ROG)의 최신 뉴스

Rogers Corp. (ROG) Tops Q1 Earnings and Revenue Estimates

Zacks Investment Research

Can These 5 Electronics Stocks Hit Targets This Earnings Season?

Zacks Investment Research

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

GlobeNewswire Inc.

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

GlobeNewswire Inc.

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

GlobeNewswire Inc.

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

GlobeNewswire Inc.

로저스 (ROG) 재무 분석

로저스 (ROG) 매출 2024

로저스 (ROG) 순이익 2024

로저스 (ROG) 현금흐름 2024

로저스 (ROG) 주당 순이익 2024